MedTrace Logo

Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients

NCT01404325 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2019-03-14

Study results available
· View outcomes & findings →

Summary

This trial evaluated the efficacy of an everolimus-based quadruple low immunosuppressive regimen versus a standard immunosuppressive regimen concerning kidney function in lung transplant recipients.

Conditions

  • Lung Transplantation

Interventions

DRUG

standard therapy

centre specific CNI-based triple drug immunosuppression

DRUG

Everolimus

quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-01
Primary Completion
2017-01-05
Completion
2017-01-05

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01404325 on ClinicalTrials.gov